The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Li-Jinn Han¹  Jia-Hui Liu¹  De-Gang Mo¹  Heng-Chen Yao²  Wei Wang²  Kang Yu³  Shou-Yong Zhao³  Tai Li⁴ 

[1] Department of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, China;Department of Cardiology, Liaocheng People's Hospital, Shandong University, Jinan, China;Department of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, China;Department of Laboratory Medicine, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, China;Department of Nursing, Liaocheng Vocational & Technical College, Liaocheng, China;

关键词: acute coronary syndrome;    insulin-like growth factor-1;    insulin-like growth factor binding protein 2;    cardiovascular prognosis;    IGF-1;    IGFBP-2;   

DOI  :  10.3389/fcvm.2023.1126093

 received in 2022-12-17, accepted in 2023-02-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundWhile insulin-like growth factor 1 (IGF-1) exerts a cardioprotective effect in the setting of atherosclerosis, insulin-like growth factor binding protein 2 (IGFBP-2) is involved in metabolic syndrome. Although IGF-1 and IGFBP-2 are known to be predictors for mortality in patients with heart failure, their use in clinic as prognostic biomarkers for acute coronary syndrome (ACS) requires investigation. We evaluated the relationship between IGF-1 and IGFBP-2 levels at admission and the risk of major adverse cardiovascular events (MACEs) in patients with ACS.MethodsA total of 277 ACS patients and 42 healthy controls were included in this prospective cohort study. Plasma samples were obtained and analyzed at admission. Patients were followed for MACEs after hospitalization.ResultsAmong patients who suffered acute myocardial infarction, plasma levels of IGF-1 and IGFBP-2 were lower and higher, respectively, as compared to healthy controls (both p < 0.05). The mean follow-up period was 5.22 (1.0–6.0) months and MACEs incidence was 22.4% (62 of 277 patients). Kaplan–Meier survival analysis revealed that patients with low IGFBP-2 levels had a greater event-free survival rate than patients with high IGFBP-2 levels (p < 0.001). Multivariate Cox proportional hazards analysis revealed IGFBP-2, but not IGF-1, to be a positive predictor of MACEs (hazard ratio 2.412, 95% CI 1.360–4.277; p = 0.003).ConclusionOur findings suggest that high IGFBP-2 levels are associated with the development of MACEs following ACS. Moreover, IGFBP-2 is likely an independent predictive marker of clinical outcomes in ACS.

【 授权许可】

Unknown   
© 2023 Wang, Yu, Zhao, Mo, Liu, Han, Li and Yao.